View in EDS

Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study

Saved in:
Bibliographic Details
Title: Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study
Authors: Lanteri-Minet, Michel, Leroux, Elizabeth, Katsarava, Zaza, Lipton, Richard B., Sakai, Fumihiko, Matharu, Manjit, Fanning, Kristina, Manack Adams, Aubrey, Sommer, Katherine, Seminerio, Michael, Buse, Dawn C.
Source: J Headache Pain
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Publisher Information: Springer Science and Business Media LLC, 2024.
Publication Year: 2024
Subject Terms: Male, Adult, Canada, Headache-related disability, Migraine Disorders, Medizin, Unmet needs, Health Services Accessibility, 03 medical and health sciences, 0302 clinical medicine, Japan, Germany, Humans, Migraine, Consultation, Research, Headache, Female [MeSH], Adult [MeSH], Health Services Accessibility/standards [MeSH], Humans [MeSH], Migraine Disorders/epidemiology [MeSH], Canada/epidemiology [MeSH], Middle Aged [MeSH], Cross-Sectional Studies [MeSH], Migraine Disorders/therapy [MeSH], Japan/epidemiology [MeSH], Germany/epidemiology [MeSH], France/epidemiology [MeSH], United Kingdom/epidemiology [MeSH], Male [MeSH], United States/epidemiology [MeSH], Barriers to care, Migraine Disorders/diagnosis [MeSH], Health Services Accessibility/statistics, Middle Aged, United States, United Kingdom, 3. Good health, Cross-Sectional Studies, Medicine, Female, France
Description: To assess rates of traversing barriers to care to access optimal clinical outcomes in people with migraine internationally.People in need of medical care for migraine should consult a health care professional knowledgeable in migraine management, obtain an accurate diagnosis, and receive an individualized treatment plan, which includes scientific society guideline-recommended treatments where appropriate.The Chronic Migraine Epidemiology and Outcomes-International (CaMEO-I) Study was a cross-sectional, web-based survey conducted from July 2021 through March 2022 in Canada, France, Germany, Japan, the United Kingdom, and the United States (US). Respondents who met modified International Classification of Headache Disorders, 3rd edition, criteria for migraine and had Migraine Disability Assessment Scale (MIDAS) scores of ≥ 6 (i.e., mild, moderate, or severe disability) were deemed to need medical care and were included in this analysis. Minimally effective treatment required that participants were currently consulting a health care professional for headache (barrier 1), reported an accurate diagnosis (barrier 2), and reported use of minimally appropriate pharmacologic treatment (barrier 3; based on American Headache Society 2021 Consensus Statement recommendations). Proportions of respondents who successfully traversed each barrier were calculated, and chi-square tests were used to assess overall difference among countries.Among 14,492 respondents with migraine, 8,330 had MIDAS scores of ≥ 6, were deemed in need of medical care, and were included in this analysis. Current headache consultation was reported by 35.1% (2926/8330) of respondents. Compared with the US, consultation rates and diagnosis rates were statistically significantly lower in all other countries except France where they were statistically significantly higher. Total appropriate treatment rates were also statistically significantly lower in all other countries compared with the US except France, which did not differ from the US. All 3 barriers were traversed by only 11.5% (955/8330) of respondents, with differences among countries (P
Document Type: Article
Other literature type
Language: English
ISSN: 1129-2377
DOI: 10.1186/s10194-024-01834-y
Access URL: https://pubmed.ncbi.nlm.nih.gov/39160483
https://doaj.org/article/35d3951a2ed94226982c1beef0ccd5ab
https://repository.publisso.de/resource/frl:6497488
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85201557684
https://doi.org/10.1186/s10194-024-01834-y
https://www.ncbi.nlm.nih.gov/pubmed/39160483
Rights: CC BY NC ND
Accession Number: edsair.doi.dedup.....63bb584d8fe9a621a99f9928a5a8d8cb
Database: OpenAIRE
Description
Abstract:To assess rates of traversing barriers to care to access optimal clinical outcomes in people with migraine internationally.People in need of medical care for migraine should consult a health care professional knowledgeable in migraine management, obtain an accurate diagnosis, and receive an individualized treatment plan, which includes scientific society guideline-recommended treatments where appropriate.The Chronic Migraine Epidemiology and Outcomes-International (CaMEO-I) Study was a cross-sectional, web-based survey conducted from July 2021 through March 2022 in Canada, France, Germany, Japan, the United Kingdom, and the United States (US). Respondents who met modified International Classification of Headache Disorders, 3rd edition, criteria for migraine and had Migraine Disability Assessment Scale (MIDAS) scores of ≥ 6 (i.e., mild, moderate, or severe disability) were deemed to need medical care and were included in this analysis. Minimally effective treatment required that participants were currently consulting a health care professional for headache (barrier 1), reported an accurate diagnosis (barrier 2), and reported use of minimally appropriate pharmacologic treatment (barrier 3; based on American Headache Society 2021 Consensus Statement recommendations). Proportions of respondents who successfully traversed each barrier were calculated, and chi-square tests were used to assess overall difference among countries.Among 14,492 respondents with migraine, 8,330 had MIDAS scores of ≥ 6, were deemed in need of medical care, and were included in this analysis. Current headache consultation was reported by 35.1% (2926/8330) of respondents. Compared with the US, consultation rates and diagnosis rates were statistically significantly lower in all other countries except France where they were statistically significantly higher. Total appropriate treatment rates were also statistically significantly lower in all other countries compared with the US except France, which did not differ from the US. All 3 barriers were traversed by only 11.5% (955/8330) of respondents, with differences among countries (P
ISSN:11292377
DOI:10.1186/s10194-024-01834-y